Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

March 17, 2019

Study Completion Date

December 28, 2022

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

Niraparib

Niraparib capsule

Trial Locations (27)

Unknown

Aichi Cancer Center Hospital, Nagoya

Hirosaki University Hospital, Hirosaki

Shikoku Cancer Center, Matsuyama

Ehime University Hospital, Tōon

Kurume University Hospital, Kurume

Hokkaido University Hospital, Sapporo

Sapporo Medical University Hospital, Sapporo

Hyogo Cancer Center, Akashi

Kansai Rosai Hospital, Amagasaki

Iwate Medical University Hospital, Morioka

Tokai University Hospital, Isehara

Nippon Medical School Musashi Kosugi Hospital, Kawasaki

Mie University Hospital, Tsu

Tohoku University Hospital, Sendai

University of the Ryukyus Hospital, Nakagami-gun

Kindai University Hospital, Sayama

Saitama Medical University International Medical Center, Hidaka

Shizuoka Cancer Center, Nagaizumi-cho

National Cancer Center Hospital, Chuo-ku

Cancer Institute Hospital, Koto-ku

The Jikei University Hospital, Minato-ku

Keio University Hospital, Shinjuku-ku

Chiba Cancer Center, Chiba

Kagoshima City Hospital, Kagoshima

Kyoto University Hospital, Kyoto

Nagasaki University Hospital, Nagasaki

Niigata University Medical & Dental Hospital, Niigata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03759587 - Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer | Biotech Hunter | Biotech Hunter